Cyheptamide
Anticonvulsant compound made from dibenzosuberone
From Wikipedia, the free encyclopedia
Cyheptamide was a investigational new drug that was developed by Ayerst Research Laboratories in the 1960s and was evaluated as an anticonvulsant.[1]
| Clinical data | |
|---|---|
| Other names | Cyheptamine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.027.792 |
| Chemical and physical data | |
| Formula | C16H15NO |
| Molar mass | 237.302 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cyheptamide undergoes significant metabolic transformation in both animals and humans, primarily through hydroxylation pathways.[2]
Cyheptamide exhibits moderate acute toxicity in animal models, with species-specific variations in lethal dose values.[3]
Related compounds
SGB-017 has a similar chemical structure and has also been evaluated for its potential use as an anticonvulsant.[4]
